Charles Democko

Mr. Democko joined Catalyst in June 2020. He was previously at CytomX, where he led the Company’s regulatory affairs and quality. Prior to CytomX, Mr. Democko was a Vice President of Regulatory Affairs at Ascendis, KaloBios, Novacea, PharmacoFore, and Connetics. Earlier in his career, Mr. Democko held regulatory affairs positions at Theravance, Elan and Genentech. Mr. Democko oversaw successful marketing applications for Activase (ischemic stroke), Myobloc (cervical dystonia), Olux (whole-body psoriasis) and Evoclin (acne), conduct of over 30 high-level meetings with FDA, EMA, and EU competent authorities, and the corporate presentation at the Activase ischemic stroke FDA advisory committee meeting, which resulted in a unanimous recommendation for approval. Mr. Democko holds a B.S. from Ohio State University.